Ask AI
ProCE Banner Activity

Targeted Therapies for HER2-Positive Gastrointestinal Cancers: Experts Answer Your Questions

Clinical Thought

In this commentary, experts answer frequently asked questions about HER2 assessment in gastric, colorectal, and other gastrointestinal cancers and how to use this information to tailor up-to-date treatment strategies. 

Released: July 12, 2023

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Seagen Inc.

Faculty Disclosure

Primary Author

Geoffrey Ku, MD

Associate Attending Physician
Gastrointestinal Oncology and Cellular Therapy Services, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York 

Geoffrey Ku, MD: researcher: Adaptimmune, AstraZeneca, Bristol Myers Squibb, CARsgen, Daiichi Sankyo, Merck, Oncolys, Pieris, Zymeworks; consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Merck, Pieris, Zymeworks.

Kanwal Raghav, MD

Professor, Gastrointestinal Medical Oncology
Associate Vice President, Ambulatory Medical Operations
Executive Medical Director, Ambulatory Treatment Centers
The University of Texas MD Anderson Cancer Center
Houston, Texas

Kanwal Raghav, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Genentech, Seattle Genetics; researcher (paid to institution): AbbVie, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Genentech, Guardant Health, HiberCell, Innovent, Janssen, Merck, Seattle Genetics, UCB Biosciences, Xencor.

Zev A. Wainberg, MD

Professor of Medicine and Surgery
Sanders Family Chair in Cancer Research
Co-Director of the UCLA GI Oncology Program
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
University of California, Los Angeles (UCLA)
Los Angeles, California

Zev A. Wainberg, MD: consultant/advisor/speaker: Amgen, Arcus, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Ipsen, Merck, Novartis, Seagen; data safety monitoring board: Mirati, Pfizer.